XML 69 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 29, 2017
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Oct. 31, 2018
Apr. 30, 2018
Mar. 31, 2018
Sep. 30, 2015
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2018
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                           $ 291,698 $ 236,178     $ 935,643 $ 1,830,639  
Grant funding liability                           5,964,931       5,964,931   $ 7,474,310
Revenue under collaborative research and development arrangements                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                           81,447 21,490     203,985 167,092  
Advaccine | Customer Concentration Risk                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Accounts receivable                           0       0   7,100,000
Advaccine | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received                                   3,000,000    
Additional revenue to be achieved                                   206,000,000    
Collaboration agreement, payment earned                                   $ 2,000,000    
Royalty period                                   10 years    
Annual maintenance fee                                   $ 1,500,000    
Annual maintenance period                                   5 years    
Revenues                                       5,000,000
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                           0       $ 0   5,000,000
ApolloBio | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received                       $ 23,000,000       $ 23,000,000   23,000,000    
Additional revenue to be achieved                                   $ 20,000,000    
Royalty period                                   10 years    
Territory expansion option period   3 years                                    
Proceeds received in upfront payment                       19,400,000                
Advisory fees                       960,000                
Period from effective date for termination                                   1 year    
Number of days written notice before termination                                   90 days    
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Foreign corporate income taxes reducing upfront payment                       2,200,000                
Foreign non-corporate income taxes reducing upfront payment                       $ 1,400,000                
AstraZeneca                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues               $ 2,000,000 $ 2,000,000                      
AstraZeneca | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received $ 27,500,000                       $ 27,500,000              
Anticipated development and regulatory event based payment receivable milestones                                 $ 125,000,000      
Anticipated commercial event based payment receivable milestones                                 $ 115,000,000      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       $ 6,900,000                                
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Accounts receivable                           2,600,000       $ 2,600,000    
Collaborative agreement, funding to be received                     $ 56,000,000                  
Collaborative agreement, period to receive funding for research and development                     5 years                  
Funding received for research and development                           2,900,000 1,600,000     7,400,000 4,600,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received           $ 9,000,000                            
Funding received for research and development                           2,600,000 1,300,000     6,100,000 9,500,000  
Grant funding liability                           2,600,000       2,600,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       5,000,000                                
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       $ 1,300,000                                
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development         $ 5,000,000                 0 943,000     893,000 1,900,000  
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development             $ 1,100,000     $ 2,200,000       137,000 164,000     137,000 334,000  
Grant funding liability                           417,000       417,000    
Department of Defence | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Contra-research and development expense                           2,400,000 $ 7,700,000     23,600,000 $ 7,700,000  
Accounts receivable                           1,300,000       1,300,000   $ 11,400,000
Deferred grant funding, from affiliate                           $ 3,000,000       $ 3,000,000    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development     $ 54,500,000                                  
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Purchase price, procurement contract     $ 16,600,000